Protocol Ledger

NCT07271667 · Phase II · RECRUITING

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Interventional Phase II clinical trial protocol NCT07271667 sponsored by Curis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-23 Enrollment: 108 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07271667
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)108 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07271667
Protocol FieldVerified Registry Value
NCT IdentifierNCT07271667
Consolidated Lead SponsorCuris
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment108 participants (ESTIMATED)
Registered Start Date2026-04-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07271667
Hospital Research SiteLocationSite Profile
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
Ohio State University Comprehensive Cancer CenterColumbus, OHOpen Hospital Dossier ->
UPMC Hillman Cancer CenterPittsburgh, PAOpen Hospital Dossier ->
Texas Oncology (Dallas)Dallas, TXOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI